CCR5 and breast cancer: Remarkably, the inhibition of CCR5 by maraviroc and vicriviroc prevents breast cancer cell invasiveness, enhances breast cancer stem killing mediated by chemotherapeutic agents targeting DNA and reduces tumor growth, angiogenesis and metastatic colonization in vivo [151,155,156].